Heat shock protein 70 enhances mucosal immunity against human norovirus when coexpressed from a vesicular stomatitis virus vector

Journal of Virology

Volumn 88, Issue 9, 2014, Pages 5122-5137

  Ma, Yuanmei ^a,b   Duan, Yue ^b   Wei, Yongwei ^b,c   Liang, Xueya ^a   Niewiesk, Stefan ^a   Oglesbee, Michael ^a   Li, Jianrong ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NINGBO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PROTEIN VP1; RECOMBINANT VESICULAR STOMATITIS VIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE GENE INSERTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE INSERTION; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NOROVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE GENE INSERTION; T LYMPHOCYTE; VESICULAR STOMATITIS; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS ATTENUATION; VIRUS PLAQUE;

ANIMALS; CAPSID PROTEINS; FEMALE; GASTROINTESTINAL TRACT; GENETIC VECTORS; HSP70 HEAT-SHOCK PROTEINS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NOROVIRUS; T-LYMPHOCYTES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VAGINA; VESICULOVIRUS; VIRAL VACCINES;

EID: 84897500598     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00019-14     Document Type: Article

References (61)

1. Farkas T, Sestak K, Wei C, Jiang X. 2008. Characterization of a rhesus monkey calicivirus representing a new genus of Caliciviridae. J. Virol. 82:5408-5416. http://dx.doi.org/10.1128/JVI.00070-08.
2. Duizer E, Schwab KJ, Neill FH, Atmar RL, Koopmans MPG, Estes MK. 2004. Laboratory efforts to cultivate noroviruses. J. Gen. Virol. 85:79-87. http://dx.doi.org/10.1099/vir.0.19478-0.
3. Donaldson EF, Lindesmith LC, Lobue AD, Baric RS. 2008. Norovirus pathogenesis: mechanisms of persistence and immune evasion in human populations. Immunol. Rev. 225:190-211. http://dx.doi.org/10.1111/j.1600-065X.2008.00680.x.
4. Estes MK, Prasad BV, Atmar RL. 2006. Noroviruses everywhere: has something changed? Curr. Opin. Infect. Dis. 19:467-474. http://dx.doi.org/10.1097/01.qco.0000244053.69253.3d.
5. Koopmans M. 2008. Progress in understanding norovirus epidemiology. Curr. Opin. Infect. Dis. 21:544-552. http://dx.doi.org/10.1097/QCO.0b013e3283108965.
6. Li J, Predmore A, Divers E, Lou F. 2012. New interventions against human norovirus: progress, opportunities, and challenges. Annu. Rev. Food Sci. Technol. 3:331-352. http://dx.doi.org/10.1146/annurev-food-022811-101234.
7. Estes MK, Ball JM, Guerrero RA, Opekun AR, Gilger MA, Pacheco SS, Graham DY. 2000. Norwalk virus vaccines: challenges and progress. J. Infect. Dis. 181(Suppl 2):S367-S373. http://dx.doi.org/10.1086/315579.
8. Jiang X, Wang M, Graham DY, Estes MK. 1992. Expression, selfassembly, and antigenicity of the Norwalk virus capsid protein. J. Virol. 66:6527-6532.
9. Prasad BV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK. 1999. X-ray crystallographic structure of the Norwalk virus capsid. Science 286:287-290. http://dx.doi.org/10.1126/science.286.5438.287.
10. Tan M, Jiang X. 2010. Norovirus gastroenteritis, carbohydrate receptors, and animal models. PLoS Pathog. 6:e1000983. http://dx.doi.org/10.1371/journal.ppat.1000983.
11. Xia M, Farkas T, Jiang X. 2007. Norovirus capsid protein expressed in yeast forms virus-like particles and stimulates systemic and mucosal immunity in mice following an oral administration of raw yeast extracts. J. Med. Virol. 79:74-83. http://dx.doi.org/10.1002/jmv.20762.
12. Ball JM, Hardy ME, Atmar RL, Conner ME, Estes MK. 1998. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J. Virol. 72:1345-1353.
13. Guerrero RA, Ball JM, Krater SS, Pacheco SE, Clements JD, Estes MK. 2001. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J. Virol. 75:9713-9722. http://dx.doi.org/10.1128/JVI.75.20.9713-9722.2001.
14. Kitamoto N, Tanaka T, Natori K, Takeda N, Nakata S, Jiang X, Estes MK. 2002. Cross-reactivity among several recombinant calicivirus viruslike particles (VLPs) with monoclonal antibodies obtained from mice immunized orally with one type of VLP. J. Clin. Microbiol. 40:2459-2465. http://dx.doi.org/10.1128/JCM.40.7.2459-2465.2002.
15. Zhang XR, Buehner NA, Hutson AM, Estes MK, Mason HS. 2006. Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein. Plant Biotechnol. J. 4:419-432. http://dx.doi.org/10.1111/j.1467-7652.2006.00191.x.
16. Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, Mendelman PM. 2011. Norovirus vaccine against experimental human Norwalk virus illness. N. Engl. J. Med. 365:2178-2187. http://dx.doi.org/10.1056/NEJMoa1101245.
17. Ma Y, Li J. 2011. Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus. J. Virol. 85:2942-2952. http://dx.doi.org/10.1128/JVI.02332-10.
18. Chen W, Lin Y, Liao C, Hsieh S. 2000. Modulatory effects of the human heat shock protein 70 on DNA vaccination. J. Biomed. Sci. 7:412-419. http://dx.doi.org/10.1007/BF02255816.
19. Todryk SM, Gough MJ, Pockley AG. 2003. Facets of heat shock protein 70 show immunotherapeutic potential. Immunology 110:1-9. http://dx.doi.org/10.1046/j.1365-2567.2003.01725.x.
20. Ciupitu AM, Petersson M, O'Donnell CL, Williams K, Jindal S, Kiessling R, Welsh RM. 1998. Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J. Exp. Med. 187:685-691. http://dx.doi.org/10.1084/jem.187.5.685.
21. Kumaraguru U, Gierynska M, Norman S, Bruce BD, Rouse BT. 2002. Immunization with chaperone-peptide complex induces low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infection. J. Virol. 76:136-141. http://dx.doi.org/10.1128/JVI.76.1.136-141.2002.
22. Milani V, Noessner E, Ghose S, Kuppner M, Ahrens B, Scharner A, Gastpar R, Issels RD. 2002. Heat shock protein 70: role in antigen presentation and immune stimulation. Int. J. Hyperthermia 18:563-575. http://dx.doi.org/10.1080/02656730210166140.
23. Millar DG, Garza KM, Odermatt B, Elford AR, Ono N, Li Z, Ohashi PS. 2003. Hsp70 promotes antigen-presenting cell function and converts Tcell tolerance to autoimmunity in vivo. Nat. Med. 9:1469-1476. http://dx.doi.org/10.1038/nm962.
24. Carsillo T, Carsillo M, Niewiesk S, Vasconcelos D, Oglesbee M. 2004. Hyperthermic pre-conditioning promotes measles virus clearance from brain in a mouse model of persistent infection. Brain Res. 1004:73-82. http://dx.doi.org/10.1016/j.brainres.2003.12.041.
25. Kim MY, Ma Y, Zhang Y, Li J, Shu Y, Oglesbee M. 2013. hsp70-dependent antiviral immunity against cytopathic neuronal infection by vesicular stomatitis virus. J. Virol. 87:10668-10678. http://dx.doi.org/10.1128/JVI.00872-13.
26. Whelan SP, Ball LA, Barr JN, Wertz GT. 1995. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc. Natl. Acad. Sci. U. S. A. 92:8388-8392. http://dx.doi.org/10.1073/pnas.92.18.8388.
27. Reeck A, Kavanagh O, Estes MK, Opekun AR, Gilger MA, Graham DY, Atmar RL. 2010. Serological correlate of protection against norovirusinduced gastroenteritis. J. Infect. Dis. 202:1212-1218. http://dx.doi.org/10.1086/656364.
28. Reiss CS, Plakhov IV, Komatsu T. 1998. Viral replication in olfactory receptor neurons and entry into the olfactory bulb and brain. Ann. N. Y. Acad. Sci. 855: 751-761. http://dx.doi.org/10.1111/j.1749-6632.1998.tb10655.x.
29. Cornish TE, Stallknecht DE, Brown CC, Seal BS, Howerth EW. 2001. Pathogenesis of experimental vesicular stomatitis virus (New Jersey serotype) infection in the deer mouse (Peromyscus maniculatus). Vet. Pathol. 38:396-406. http://dx.doi.org/10.1354/vp.38-4-396.
30. Wertz GW, Perepelitsa VP, Ball LA. 1998. Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus. Proc. Natl. Acad. Sci. U. S. A. 95:3501-3506. http://dx.doi.org/10.1073/pnas.95.7.3501.
31. Ahmed M, Marino TR, Puckett S, Kock ND, Lyles DS. 2008. Immune response in the absence of neurovirulence in mice infected withmprotein mutant vesicular stomatitis virus. J. Virol. 82:9273-9277. http://dx.doi.org/10.1128/JVI.00915-08.
32. Fang X, Zhang S, Sun X, Li J, Sun T. 2012. Evaluation of attenuated VSVs with mutated M or/and G proteins as vaccine vectors. Vaccine 30: 1313-1321. http://dx.doi.org/10.1016/j.vaccine.2011.12.085.
33. Schnell MJ, Johnson JE, Buonocore L, Rose JK. 1997. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 90:849-857. http://dx.doi.org/10.1016/S0092-8674(00)80350-5.
34. Whelan SP, Barr JN, Wertz GW. 2004. Transcription and replication of nonsegmented negative-strand RNA viruses. Curr. Top. Microbiol. Immunol. 283:61-119.
35. Carsillo T, Carsillo M, Traylor Z, Rajala-Schultz P, Popovich P, Niewiesk S, Oglesbee M. 2009. Major histocompatibility complex haplotype determines hsp70-dependent protection against measles virus neurovirulence. J. Virol. 83:5544-5555. http://dx.doi.org/10.1128/JVI.02673-08.
36. Kim MY, Shu Y, Carsillo T, Zhang J, Yu L, Peterson C, Longhi S, Girod S, Niewiesk S, Oglesbee M. 2013. hsp70 and a novel axis of type I interferon-dependent antiviral immunity in the measles virus-infected brain. J. Virol. 87:998-1009. http://dx.doi.org/10.1128/JVI.02710-12.
37. Li J, Jiang P, Li Y, Wang X, Cao J, Zeshan B. 2009. HSP70 fused with GP3 and GP5 of porcine reproductive and respiratory syndrome virus enhanced the immune responses and protective efficacy against virulent PRRSV challenge in pigs. Vaccine 27:825-832. http://dx.doi.org/10.1016/j.vaccine.2008.11.088.
38. Fei-fei G, Jian W, Feng X, Li-ping S, Quan-yun S, Jin-ping Z, Pu-yan C, Pei-hong L. 2008. Japanese encephalitis protein vaccine candidates expressing neutralizing epitope and M.T hsp70 induce virus-specific memory B cells and long-lasting antibodies in swine. Vaccine 26:5590-5594. http://dx.doi.org/10.1016/j.vaccine.2008.07.104.
39. Ge FF, Qiu YF, Yang YW, Chen PY. 2007. An hsp70 fusion protein vaccine potentiates the immune response against Japanese encephalitis virus. Arch. Virol. 152:125-135. http://dx.doi.org/10.1007/s00705-006-0822-z.
40. Li J, Li KN, Gao J, Cui JH, Liu YF, Yang SJ. 2008. Heat shock protein 70 fused to or complexed with hantavirus nucleocapsid protein significantly enhances specific humoral and cellular immune responses in C57BL/6 mice. Vaccine 26:3175-3187. http://dx.doi.org/10.1016/j.vaccine.2008.02.066.
41. Zeng R, Zhang Z, Mei X, Gong W, Wei L. 2008. Protective effect of a RSV subunit vaccine candidate G1F/M2 was enhanced by a HSP70-like protein in mice. Biochem. Biophys. Res. Commun. 377:495-499. http://dx.doi.org/10.1016/j.bbrc.2008.10.002.
42. Zhang X, Glendening C, Linke H, Parks CL, Brooks C, Udem SA, Oglesbee M. 2002. Identification and characterization of a regulatory domain on the carboxyl terminus of the measles virus nucleocapsid protein. J. Virol. 76:8737-8746. http://dx.doi.org/10.1128/JVI.76.17.8737-8746.2002.
43. Zhang X, Bourhis JM, Longhi S, Carsillo T, Buccellato M, Morin B, Canard B, Oglesbee M. 2005. Hsp72 recognizes a P binding motif in the measles virus N protein C-terminus. Virology 337:162-174. http://dx.doi.org/10.1016/j.virol.2005.03.035.
44. Keller R, Dwyer JE. 1968. Neutralization of poliovirus by IgA coproantibodies. J. Immunol. 101:192-202.
45. Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH. 1991. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J. Infect. Dis. 163:1-6. http://dx.doi.org/10.1093/infdis/163.1.1.
46. Buisman AM, Abbink F, Schepp RM, Sonsma JA, Herremans T, Kimman TG. 2008. Preexisting poliovirus-specific IgA in the circulation correlates with protection against virus excretion in the elderly. J. Infect. Dis. 197:698-706. http://dx.doi.org/10.1086/527487.
47. Hjelt K, Grauballe PC, Paerregaard A, Nielsen OH, Krasilnikoff PA. 1987. Protective effect of preexisting rotavirus-specific immunoglobulin A against naturally acquired rotavirus infection in children. J. Med. Virol. 21:39-47. http://dx.doi.org/10.1002/jmv.1890210106.
48. Matson DO, O'Ryan ML, Herrera I, Pickering LK, Estes MK. 1993. Fecal antibody responses to symptomatic and asymptomatic rotavirus infections. J. Infect. Dis. 167:577-583. http://dx.doi.org/10.1093/infdis/167.3.577.
49. Wyatt RG, Greenberg HB, Dalgard DW, Allen WP, Sly DL, Thornhill TS, Chanock RM, Kapikian AZ. 1978. Experimental infection of chimpanzees with the Norwalk agent of epidemic viral gastroenteritis. J. Med. Virol. 2:89-96. http://dx.doi.org/10.1002/jmv.1890020203.
50. Okhuysen PC, Jiang X, Ye L, Johnson PC, Estes MK. 1995. Viral shedding and fecal IgA response after Norwalk virus infection. J. Infect. Dis. 171:566-569. http://dx.doi.org/10.1093/infdis/171.3.566.
51. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. 2003. Humoral, mucosal, and cellular immune responses to oral Norwalk viruslike particles in volunteers. Clin. Immunol. 108:241-247. http://dx.doi.org/10.1016/S1521-6616(03)00120-7.
52. Souza M, Cheetham SM, Azevedo MS, Costantini V, Saif LJ. 2007. Cytokine and antibody responses in gnotobiotic pigs after infection with human norovirus genogroup II.4 (HS66 strain). J. Virol. 81:9183-9192. http://dx.doi.org/10.1128/JVI.00558-07.
53. Souza M, Azevedo MS, Jung K, Cheetham S, Saif LJ. 2008. Pathogenesis and immune responses in gnotobiotic calves after infection with the genogroup II.4-HS66 strain of human norovirus. J. Virol. 82:1777-1786. http://dx.doi.org/10.1128/JVI.01347-07.
54. Roberts A, Buonocore L, Price R, Forman J, Rose JK. 1999. Attenuated vesicular stomatitis viruses as vaccine vectors. J. Virol. 73:3723-3732.
55. Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, Donahoe SM, Montefiori D, Roberts A, Buonocore L, Rose JK. 2001. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106:539-549. http://dx.doi.org/10.1016/S0092-8674(01)00482-2.
56. Majid AM, Ezelle H, Shah S, Barber GN. 2006. Evaluating replicationdefective vesicular stomatitis virus as a vaccine vehicle. J. Virol. 80:6993-7008. http://dx.doi.org/10.1128/JVI.00365-06.
57. Tan GS, McKenna PM, Koser ML, McLinden R, Kim JH, McGettigan JP, Schnell MJ. 2005. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Virology 331:82-93. http://dx.doi.org/10.1016/j.virol.2004.10.018.
58. Buonocore L, Blight KJ, Rice CM, Rose JK. 2002. Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J. Virol. 76:6865-6872. http://dx.doi.org/10.1128/JVI.76.14.6865-6872.2002.
59. Faber M, Lamirande EW, Roberts A, Rice AB, Koprowski H, Dietzschold B, Schnell MJ. 2005. A single immunization with a rhabdovirusbased vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARSCoV-neutralizing antibodies. J. Gen. Virol. 86(Pt 5):1435-1440. http://dx.doi.org/10.1099/vir.0.80844-0.
60. Kapadia SU, Rose JK, Lamirande E, Vogel L, Subbarao K, Roberts A. 2005. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340:174-182. http://dx.doi.org/10.1016/j.virol.2005.06.016.
61. Geisbert TW, Daddario-DiCaprio KM, Geisbert JB, Reed DS, Feldmann F, Grolla A, Stroeher U, Fritz EA, Hensley LE, Jones SM, Feldmann H. 2008. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26:6894-6900. http://dx.doi.org/10.1016/j.vaccine.2008.09.082.